{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:46:15Z","timestamp":1762332375362,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejpb.2025.114775","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T19:00:43Z","timestamp":1749236443000},"page":"114775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A questionnaire survey on the barriers regarding pharmaceutical excipients during pediatric drug development"],"prefix":"10.1016","volume":"214","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4799-5562","authenticated-orcid":false,"given":"Jumpei","family":"Saito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidefumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Akabane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akimasa","family":"Yamatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2025.114775_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121501","article-title":"Paediatric specific dosage forms: patient and formulation considerations","volume":"616","author":"Khan","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114775_b0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejps.2015.12.018","article-title":"Pharmaceutical excipients - quality, regulatory and biopharmaceutical considerations","volume":"87","author":"Elder","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"issue":"7","key":"10.1016\/j.ejpb.2025.114775_b0015","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.xphs.2016.03.019","article-title":"An overview of pharmaceutical excipients: safe or not safe?","volume":"105","author":"Abrantes","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2025.114775_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122571","article-title":"A review on taste masked multiparticulate dosage forms for paediatric","volume":"632","author":"Al-Japairai","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114775_b0025","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40005-017-0354-4","article-title":"Excipient risk assessment: possible approaches to assessing the risk associated with excipient function","volume":"48","author":"Ruban","year":"2018","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.ejpb.2025.114775_b0030","first-page":"453","article-title":"The current states, challenges, ongoing efforts, and future perspectives of pharmaceutical excipients in pediatric patients in each country and region","volume":"9","author":"Saito","year":"2022","journal-title":"Children (Basel)."},{"key":"10.1016\/j.ejpb.2025.114775_b0035","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ijpharm.2017.07.042","article-title":"Challenges and strategies to facilitate formulation development of pediatric drug products: safety qualification of excipients","volume":"536","author":"Buckley","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114775_b0040","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology\u2013drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 10","key":"10.1016\/j.ejpb.2025.114775_b0045","first-page":"S10","article-title":"Developmental changes in Pharmacokinetics and Pharmacodynamics","volume":"58","author":"van den Anker","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2025.114775_b0050","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1517\/14740338.2011.565328","article-title":"Safety issues with ethanol as an excipient in drugs intended for pediatric use","volume":"10","author":"Zuccotti","year":"2011","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ejpb.2025.114775_b0055","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/FTD.0000000000000003","article-title":"Low but inducible contribution of renal elimination to clearance of propylene glycol in preterm and term neonates","volume":"36","author":"De Cock","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejpb.2025.114775_b0060","unstructured":"IPEC. The International Pharmaceutical Excipients Council, Qualification of Excipients for Use in Pharmaceuticals. Available online at: https:\/\/ipecamericas.org\/sites\/default\/files\/ExcipientQualificationGuide.pdf [accessed 24 Nov 2024]."},{"key":"10.1016\/j.ejpb.2025.114775_b0065","unstructured":"Al-khattawi A and Mohammed, AR. Excipients in medicines for children: scientific and regulatory paradigms. European Pharmaceutical Review 2014. Available online at: https:\/\/www.europeanpharmaceuticalreview.com\/article\/24946\/excipients-medicines-children-scientific-regulatory-paradigms [accessed 16 Nov 2020]."},{"key":"10.1016\/j.ejpb.2025.114775_b0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.addr.2013.11.003","article-title":"Risk assessment of neonatal excipient exposure: lessons from food safety and other areas","volume":"73","author":"Turner","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2025.114775_b0075","first-page":"251","article-title":"Excipients in neonatal medicinal products: never prescribed commonly administered","volume":"32","author":"Valeur","year":"2018","journal-title":"Pharmaceut. Med."},{"key":"10.1016\/j.ejpb.2025.114775_b0080","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/pharmaceutics13030387","article-title":"Excipients in the paediatric population: a review","volume":"13","author":"Rouaz","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2025.114775_b0085","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/pharmaceutics16010119","article-title":"Potentially Harmful excipients: state of the art for Oral liquid forms used in neonatology and pediatrics units","volume":"16","author":"Bobillot","year":"2024","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2025.114775_b0090","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/archdischild-2014-307793","article-title":"ESNEE consortium. potentially harmful excipients in neonatal medicines: a pan-European observational study","volume":"100","author":"Nellis","year":"2015","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ejpb.2025.114775_b0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40780-021-00208-9","article-title":"Potentially harmful excipients in neonatal medications: a multicenter nationwide observational study in Japan","volume":"7","author":"Saito","year":"2021","journal-title":"J. Pharm. Health Care Sci."},{"key":"10.1016\/j.ejpb.2025.114775_b0100","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejpb.2020.12.021","article-title":"Best practices for selection of excipients for paediatrics - workshop reflection","volume":"160","author":"Salunke","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114775_b0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2012.05.004","article-title":"The STEP (safety and toxicity of excipients for paediatrics) database. Part 1-a need assessment study","volume":"435","author":"Salunke","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114775_b0110","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijpharm.2013.09.013","article-title":"The STEP (safety and toxicity of excipients for paediatrics) database: part 2 - the pilot version","volume":"457","author":"Salunke","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114775_b0115","doi-asserted-by":"crossref","unstructured":"EFSA Panel on Food Additives and Flavourings (FAF); Younes M, Aquilina G, Castle L, Engel KH, Fowler P, Frutos Fernandez MJ, F\u00fcrst P, Gundert-Remy U, G\u00fcrtler R, Hus\u00f8y T, Manco M, Mennes W, Moldeus P, Passamonti S, Shah R, Waalkens-Berendsen I, W\u00f6lfle D, Corsini E, Cubadda F, De Groot D, FitzGerald R, Gunnare S, Gutleb AC, Mast J, Mortensen A, Oomen A, Piersma A, Plichta V, Ulbrich B, Van Loveren H, Benford D, Bignami M, Bolognesi C, Crebelli R, Dusinska M, Marcon F, Nielsen E, Schlatter J, Vleminckx C, Barmaz S, Carf\u00ed M, Civitella C, Giarola A, Rincon AM, Serafimova R, Smeraldi C, Tarazona J, Tard A, Wright M. Safety assessment of titanium dioxide (E171) as a food additive. EFSA J. 2021;19:e06585. doi: 10.2903\/j.efsa.2021.6585.","DOI":"10.2903\/j.efsa.2021.6585"},{"key":"10.1016\/j.ejpb.2025.114775_b0120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12989-023-00533-x","article-title":"Oral toxicological study of titanium dioxide nanoparticles with a crystallite diameter of 6 nm in rats","volume":"20","author":"Akagi","year":"2023","journal-title":"Part Fibre Toxicol."},{"key":"10.1016\/j.ejpb.2025.114775_b0125","unstructured":"The European Commission. Commission Regulation (EU) 2022\/63 of 14 January 2022 amending Annexes II and III to Regulation (EC) No 1333\/2008 of the European Parliament and of the Council as regards the food additive titanium dioxide (E 171). Official Journal of the European Union 2022, p. 1\u20135. http:\/\/data.europa.eu\/eli\/reg\/2022\/63\/oj [accessed 24 Feb 2025]."},{"key":"10.1016\/j.ejpb.2025.114775_b0130","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/0192623313495603","article-title":"Regulatory forum opinion piece: supporting the need for international harmonization of safety assessments for food flavoring substances","volume":"42","author":"Konishi","year":"2014","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ejpb.2025.114775_b0135","doi-asserted-by":"crossref","unstructured":"EFSA Panel on Food Additives and Nutrient Sources added to Food. Scientific Opinion on the re-evaluation of iron oxides and hydroxides (E 172) as food additives. EFSA Journal 2015;13(12):4317.","DOI":"10.2903\/j.efsa.2015.4317"},{"key":"10.1016\/j.ejpb.2025.114775_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114458","article-title":"Selecting appropriate excipients for paediatric dosage form - paediatric excipients risk assessment (PERA) framework - Part 1","volume":"203","author":"Salunke","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2025.114775_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114447","volume":"203","author":"Agrawal","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125001523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125001523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:41:16Z","timestamp":1762332076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641125001523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":29,"alternative-id":["S0939641125001523"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114775","relation":{},"ISSN":["0939-6411"],"issn-type":[{"type":"print","value":"0939-6411"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A questionnaire survey on the barriers regarding pharmaceutical excipients during pediatric drug development","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114775"}}